SAGE Therapeutics (SAGE) Tops Q1 EPS by 27c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sage Therapeutics Announces First Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
May 4, 2021 6:30 AM EDTCompany on-track to initiate placebo-controlled Phase 2 trial with SAGE-718 in Huntingtons disease in late 2021, as the target for the first indication for SAGE-718, following encouraging signals in Phase 1 data
PARADIGM Study with SAGE-718 showed improved performance from baseline on multiple tests of executive function over 14 days of treatment in patients with Parkinsons disease cognitive impairment, further supporting development in disorders associated with cognitive dysfunction
Positive topline data from Phase 2 KINETIC Study showed statistically significant reduction in tremor score with SAGE-324 compared to placebo at Day 29 in adults... More
